Retail Clinics

WASHINGTON McNeil products soon will repopulate shelves, Johnson & Johnson chairman and CEO Bill Weldon shared on Thursday during his testimony before the House of Representatives Committee on Oversight and Government Reform.

PITTSBURGH Mylan has launched a generic version of a common antidepressant, the company said Friday.

Mylan announced the launch of bupropion hydrochloride extended-release tablets in the 150-mg and 300-mg strengths, a once-daily treatment for depression.

The drug is a generic version of GlaxoSmithKline’s Wellbutrin XL. Various versions of the drug had sales of around $752 million during the 12-month period ended in June, according to IMS Health.

WASHINGTON Due to the nation’s deep recession, states experienced rapid growth in their Medicaid enrollment and spending last year and expect additional growth, though at a slower pace, in fiscal year 2011, according to a survey of state Medicaid officials in all 50 states released Thursday by the Kaiser Family Foundation’s Commission on Medicaid and the Uninsured.

MUMBAI, India The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Sun Pharmaceutical Industries.

Sun announced Wednesday the tentative approval of rosuvastatin calcium tablets in the 5-mg, 10-mg, 20-mg and 40-mg strengths.

ABBOTT PARK, Ill. Abbott has received market clearance from the Food and Drug Administration for RevitaLens Ocutec, a multipurpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.

PHILADELPHIA GlaxoSmithKline has tapped soccer star Mia Hamm for its public health campaign to emphasize the need for adults to make vaccinations part of their overall health-and-wellness goals.

GSK's Give Your Health a Shot campaign underscores the need for adults to receive vaccinations as a preventative measure to protect their health. The campaign announcement followed the pertussis (whooping cough) outbreak that has affected California.

ST. PETERSBURG, Fla. Smith & Nephew has created a liquid film-forming dressing that dries in less than 30 seconds.

The company's alcohol-free No-Sting Skin-Prep spray has a four-day wear time and leaves a clear, waterproof, breathable and conformable barrier that allows for visual assessment of the periwound area.

BURLINGTON, Mass. The drug market for Crohn's disease treatments will see moderate growth over the next decade, Decision Resources reported Wednesday.

The research firm projected that the market will increase a little more than 31%, from $3.2 billion in 2009 to $4.2 billion in 2019, in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Decision Resources said the the modest growth rate masks such market changes as new and emerging biologics, as well as generic competition.